Basilea names new commercial head
This article was originally published in Scrip
Executive Summary
Basilea Pharmaceutica, which develops products in the therapeutic areas of bacterial infections, fungal infections and oncology, has named David Veitch chief commercial officer – effective 1 September 2014. Mr Veitch will be responsible for leading Basilea's commercial operations, including sales, marketing, pricing and market access, and will report to chief executive officer Ronald Scott. Prior to joining the Basel, Switzerland-based firm, Mr Veitch was president of European operations at Savient Pharmaceuticals.